In this review, we cover the evolution of knowledge on the biology of prostate-specific
membrane antigen (PSMA) and its translation to therapy. The usual key to discovery is a …

The aim of this review is to report on the current status of prostate-specific membrane
antigen (PSMA)-directed theranostics in prostate cancer (PC) patients. The value of 68 Ga …

Background: Stratifying prostate cancer (PCa) patients into risk groups at time of initial
diagnosis enabling a risk-adapted disease management is still a major clinical challenge …

Prostate-specific membrane antigen (PSMA) is a type II transmembrane glycoprotein that is
highly overexpressed on prostate cancer epithelial cells and for which there is a growing …

Biomarkers are an integral part of cancer management due to their use in risk assessment,
screening, differential diagnosis, prognosis, prediction of response to treatment, and …

The rising incidence rate of the cancer in the prostate gland has increased the demand for
improved diagnostic, imaging, and therapeutic approaches. Prostate-specific membrane …

Objectives Prostate-specific membrane antigen (PSMA) positron emission
tomography/computed tomography (PET/CT) is used for detection and (re) staging of …

Aim PSMA (prostate-specific membrane antigen) is physiologically expressed in normal
prostate tissue and over expressed in prostate cancer cells, therefore constituting a potential …

Folate-targeted liposomes (FTL) were tested as drug delivery vehicles to PSMA-positive
cancer cells. We used FL with co-entrapped mitomycin C lipophilic prodrug (MLP) and …

T cells express receptors on their surfaces (ie, T cell receptors) that recognize antigens
presented on the surface of antigen-presenting cells. During a normal immune response …